PDF file: 441-2168_Ivermectin_part_2_phil.pdf
OPQ ID: 441-2168
Session: 441
Question number: Q-2168
Sessional paper: Q-2168
Title: Ivermectin part 2, phil
Short description: 
Topic: public health
Identified concern: 
Keywords: 
Agencies: HC, PHAC
Date asked: 2023-12-13
Date tabled: 
Submitted by: Mr. Epp (Chatham-Kent—Leamington)
Reply by: Minister of Health
Responded by: the Honourable Mark Holland
Pages: 2
Status: not processed
Alert: yellow
Questions asked: 6
Questions answered: 4
Percent responded: 67%
Referenced sources: (none extracted)
Referenced links: (none extracted)
Official link: https://www.google.com/search?q=Q-2168+ourcommons.ca
PDF URL: https://ivim.ca/foi/opq/r/441-2168_Ivermectin_part_2_phil.pdf
TXT URL: https://ivim.ca/foi/opq/r/441-2168.txt
Original filename: Q-2168_HC, Ivermectin part 2, phil.pdf
Local source path: C:\Users\Dmitry\Documents\CODES\OPQ-App\data-raw\OPQ\ALL OPQ TO DATE\2022\Q-2168_HC, Ivermectin part 2, phil.pdf
Machine extracted at: 2026-06-30 12:58:25

References / links:
(none extracted)

Machine notes:
(none)

Question text preview:
With regard to the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 (the Interim
Order) on September 16, 2020: (a) does the Minister of Health require an application by the manufacturer to approve a drug that is already approved for another indication;
(b) what is the total number of inquiries received by Health Canada and the Public Health Agency of Canada about Ivermectin for the prophylaxis and treatment of COVID- 19;
(c) how many inquiries have been made to Health Canada and the Public
Health Agency of Canada about Ivermectin for the prophylaxis and treatment of COVID-19, broken down by (i) the general public (ii) healthcare clinicians, (iii) researchers, (iv) provincial and territorial health authorities, (v) hospitals, (vi) long-term care facilities, (vii) healthcare practitioners' regulatory governing bodies, (viii) Members of provincial, territorial and federal Parliament (ix) organizations; and (d) what is the number of signatures on any petitions related to Ivermectin?